Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Elsevier Science full text link Elsevier Science Free PMC article
Full text links

Actions

Share

Comment
.2013 Oct;11(10):1232-9.
doi: 10.1016/j.cgh.2013.04.029. Epub 2013 May 2.

Methods for diagnosis of bile acid malabsorption in clinical practice

Affiliations
Comment

Methods for diagnosis of bile acid malabsorption in clinical practice

Priya Vijayvargiya et al. Clin Gastroenterol Hepatol.2013 Oct.

Abstract

Altered concentrations of bile acid (BA) in the colon can cause diarrhea or constipation. More than 25% of patients with irritable bowel syndrome with diarrhea or chronic diarrhea in Western countries have BA malabsorption (BAM). As BAM is increasingly recognized, proper diagnostic methods are needed to help direct the most effective course of treatment for the chronic bowel dysfunction. We review the methodologies, advantages, and disadvantages of tools that directly measure BAM: the (14)C-glycocholate breath and stool test, the (75)selenium homotaurocholic acid test (SeHCAT), and measurements of 7 α-hydroxy-4-cholesten-3-one (C4) and fecal BAs. The (14)C-glycocholate test is laborious and no longer widely used. The (75)SeHCAT has been validated but is not available in the United States. Measurement of serum C4 is a simple and accurate method that can be used for most patients but requires further clinical validation. Assays to quantify fecal BA (total and individual levels) are technically cumbersome and not widely available. Regrettably, none of these tests are routinely available in the United States; assessment of the therapeutic effects of a BA binder is used as a surrogate for diagnosis of BAM. Recent data indicate the advantages to studying fecal excretion of individual BAs and their role in BAM; these could support the use of the fecal BA assay, compared with other tests. Measurement of fecal BA levels could become a routine addition to the measurement of fecal fat in patients with unexplained diarrhea. Availability ultimately determines whether the C4, SeHCAT, or fecal BA test is used; more widespread availability of such tests would enhance clinical management of these patients.

Keywords: (75)SeHCAT; (75)selenium homotaurocholic acid test; 7 α-hydroxy-4-cholesten-3-one; ASBT; BA; BAM; C4; CA; CDCA; CYP7A1; DCA; Diarrhea; Fecal; GC-MS; Glycocholate; HPLC; IBAT; IBS; LCA; MS; NADH; Na(+)-dependent bile salt transporter; SeHCAT; bile acid; bile acid malabsorption; chenodeoxycholic acid; cholesterol 7α hydroxylase; cholic acid; deoxycholic acid; gas chromatography–mass spectrometry; high-performance liquid chromatography; ileal BA transporter; irritable bowel syndrome; lithocholic acid; mass spectrometry; reduced nicotinamide adenine dinucleotide.

Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Bile acid (BA) chemistry: chenodeoxycholic acid (CDCA), cholic acid (CA), deoxycholic acid (DCA), lithocholic acid (LCA) and ursodeoxycholic acid (UDCA). Reproduced from Bajor A, et al. Scand J Gastroenterol 2010;45:645-664.
Figure 2
Figure 2
Hepatic synthesis of BA from cholesterol involves entry into hepatocytes of lowdensity lipoprotein (LDL) cholesterol by binding to LDL receptors on the hepatocyte cell surface. Upregulation of hepatic BA synthesis promotes maintenance of BA pool size and leads to an increase in serum 7 α-hydroxy-4-cholesten-3-one (C4), a surrogate for the activity of cholesterol 7 α-hydroxylase, the rate-limiting enzyme in hepatic BA synthesis. Adapted from Wong BS, et al. Am J Gastroenterol 2011;106:2154-2164.
Figure 3
Figure 3
Variation in BA excretion per gram fecal weight in each bowel movement (BM) in a single patient. Data show median, interquartile range, 5th and 95th percentiles, and each individual value. Reproduced from Mitchell WD, et al. Gut 1973;14:348-353.
Figure 4A and B
Figure 4A and B
(A)75SeHCAT values and total fecal bile acids of nine patients. Vertical dotted line marks the lower normal limit for total fecal bile acids (250mg/day). Reproduced from Sciaretta G, et al. Gut 1987;28:970-975. (B) Relationship between half-life of75SeHCAT and HCO (7 α-hydroxy-4-cholesten-3-one) serum concentrations in patients with diarrhea of unknown origin. The response to treatment is indicated by different symbols (formula image = response to treatment, ■ = no response to treatment, ● = response not evaluated). The hatched area denotes pathologic values for both tests; the dotted area denotes normal values for both tests. Reproduced from Sauter GH, et al. Dig Dis Sci 1999;44:14-19.
Figure 5A, B and C
Figure 5A, B and C
(A and B) Quantification of serum C4 and total stool bile acids in IBS-C, IBS-D and healthy controls. Data show median and interquartile ranges, 5th and 95th percentiles. Note the higher serum C4 and fecal total bile acids excreted over 48 hours in patients with IBS-D. (C) Relationship between fasting serum C4 and total 48 hour stool BA excretion. Adapted from Wong BS, et al. Clin Gastroenterol Hepatol 2012;10:1009-1015.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hofmann AF, Small DM. Detergent properties of bile salts: correlation with physiological function. Annu Rev Med. 1967;18:333–376. - PubMed
    1. Rao AS, Wong B, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010;139:1549–1558. - PMC - PubMed
    1. Alnouti Y. Bile acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci. 2009;108:224–246. - PubMed
    1. Robben J, Caenepeel P, Van Eldere J, et al. Effects of intestinal microbial bile salt sulfatase activity on bile salt kinetics in gnotobiotic rats. Gastroenterology. 1988;94:494–502. - PubMed
    1. Breuer NF, Rampton DS, Tammar A, et al. Effect of colonic perfusion with sulfated and nonsulfated bile acids on mucosal structure and function in the rat. Gastroenterology. 1983;84:969–977. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Elsevier Science full text link Elsevier Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp